| Document |
Document Title |
|
WO/2023/006087A1 |
Provided are a macrocyclic pyridone compound and an application thereof in preparation of drugs for treating related diseases. Specifically, provided are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/009774A1 |
The disclosed technology relates to compositions suitable for use as lubricants and lubricant additive compositions which comprise a 1,4-benzoxazine-derived antioxidant, wherein the antioxidant itself may also be described as a 1,4-benzo...
|
|
WO/2023/001141A1 |
Provided novel compounds useful as KRAS G12D inhibitors, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical compositions.
|
|
WO/2023/004257A1 |
Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using s...
|
|
WO/2023/002443A1 |
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certai...
|
|
WO/2023/001123A1 |
Provided in the present invention are a new pyridopyrimidine derivative, a pharmaceutically acceptable salt, an ester, a stereoisomer or a tautomer, and a pharmaceutical composition containing same and the use thereof. The compound of th...
|
|
WO/2023/001069A1 |
A series of macrocyclic amide compounds and an application thereof. Specifically disclosed are a compound as represented by formula (V) or a pharmaceutically acceptable salt thereof and an application thereof.
|
|
WO/2023/001229A1 |
The present invention relates to a pyrimidocyclic derivative, a preparation method therefor, and a medical application of a pharmaceutical composition containing the derivative. Specifically, the present invention relates to a substitute...
|
|
WO/2023/000114A1 |
Bioconjugates are described comprising alpha-fetoprotein (AFP) linked with a cytotoxin through a disulfide, glutathione-sensitive linker, for cancer treatment. In a preferred embodiment, the bioconjugate is an AFP variant linked with a m...
|
|
WO/2023/002011A1 |
The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity...
|
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/282236A1 |
This rare earth complex is represented by a general formula (1). (In the formula, HC is a quinolinonato ligand and cumalinato ligand; L1 is a nitrogen-containing ligand, etc.; L2 is water, etc.; XL is a halide ion, etc.; M3+ is a trivale...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/280317A1 |
Provided are a benzylamino tricyclic compound and the use thereof, which in particular relate to a compound as represented by formula (Ⅹ), and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/275199A1 |
The invention provides a compound according to formula (I) or a tautomer thereof, wherein R1, R2, R3, W1, W2, W3, A, X and Y are as defined in the specification. The compounds are potent inhibitors of the serine/threonine kinase, TAK1. T...
|
|
WO/2023/274383A1 |
A KRAS inhibitor compound represented by formula (I), and an isomer or a pharmaceutically acceptable salt thereof. The compound represented by formula (I) and the composition thereof can effectively treat diseases related to KRAS mutation.
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/279041A1 |
Disclosed herein are compounds and methods of treating diseases and/or conditions associated with FGFR inhibition.
|
|
WO/2022/268180A1 |
Provided is a compound as represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound has a relatively strong MAT2A inhibitory effect...
|
|
WO/2022/268051A1 |
The present disclosure relates to a fused tetracyclic compound, a preparation method therefor and an application thereof in medicine. Specifically, the present disclosure relates to a fused tetracyclic compound as shown in general formul...
|
|
WO/2022/272129A1 |
Disclosed herein are pharmaceutical compositions comprising biosynthetic allosteric mTOR inhibitors that can have improved pharmacology and reduced toxicity. Also disclosed herein are methods of treating a condition or disease by adminis...
|
|
WO/2022/269508A1 |
The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compo...
|
|
WO/2022/272060A1 |
Described herein are compounds that are EP2 antagonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of diseases or conditi...
|
|
WO/2022/262590A1 |
Provided is a two-step resin purification process of ansamitocin. Specifically, by means of multi-step resin extraction and desorption followed by combination and concentration, a target product is obtained. The process comprises at leas...
|
|
WO/2022/266069A1 |
The present embodiments provide compounds of Formula I, compositions of the compounds, and methods for treating diseases such as cancer.
|
|
WO/2022/264974A1 |
The purpose of the present invention is to provide a compound which absorbs light having a wavelength of 400-410 nm from sunlight, does not affect a material inside an organic EL element, and has a high refractive index in a wavelength r...
|
|
WO/2022/262615A1 |
The present invention relates to an anthracene compound of formula A, a preparation method therefor, and a medical use thereof. The anthracene compound has the effect of inhibiting the growth of tumor cells, and has the potential as an a...
|
|
WO/2022/263627A1 |
The present invention relates to polymer derivatives of mertansine (DM1) or of analogues thereof (e.g., DM4), preferably to polyacrylamide derivatives, of formula (A), or a pharmaceutically acceptable salt and/or solvate thereof, wherein...
|
|
WO/2022/262591A1 |
A method for purifying ansamitocin P-3, comprising using a resin to adsorb an ansamitocin fermentation solution, using an organic solvent for resolution, collecting and concentrating a resolution solution, subjecting the resolution solut...
|
|
WO/2022/266236A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/261154A1 |
The present invention provides compounds of the formula where R1, R2, R3, R4a, R4b, R4c, R5, R6, X, Y, and Z are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically ac...
|
|
WO/2022/258057A1 |
Disclosed are the compounds of formula I, their use as inhibitors of pan KRAS :: SOS1, their pharmaceutical compositions and their use as medicaments uses, especially as agents for the treatment of oncological diseases including cancer.
|
|
WO/2022/256702A1 |
Compounds of formula I and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and m...
|
|
WO/2022/255889A1 |
The present invention provides novel compounds which bind to cereblon, and methods of use thereof. The compounds are represented by Formulas (I), (II), (III), (IV), (V) and (VI):
|
|
WO/2022/256676A1 |
Compounds of formula I, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and ...
|
|
WO/2022/253328A1 |
An HPK1 kinase inhibitor, and a preparation method therefor and an application thereof. Specifically, a compound shown in formula (I), the compound having HPK1 inhibitory activity and being used for preparing a pharmaceutical composition...
|
|
WO/2022/247641A1 |
Provided are a new class of compounds having a WEE1 inhibitory effect and as represented by formula I, and the use thereof in the preparation of a drug.
|
|
WO/2022/247770A1 |
A nitrogen-containing heterocyclic compound, a preparation method therefor and an application thereof. A nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer there...
|
|
WO/2022/251306A1 |
The present disclosure provides, inter alia, a compound having the structure of Formula (1): Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. F...
|
|
WO/2022/247759A1 |
Disclosed in the present invention are an intermediate of a pyridone derivative and a preparation method therefor. The new intermediate compound of formula I, compound of formula E or compound of formula C of the present invention can be...
|
|
WO/2022/251304A1 |
The present invention provides compounds (I) useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/251567A1 |
Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18.
|
|
WO/2022/251302A1 |
The present invention provides compounds useful as orexin-2 receptor agonists for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/247839A1 |
The present invention relates to the technical field of medicines, and in particular, to a PARP7 kinase inhibitor compound represented by general formula (I), a pharmaceutically acceptable salt or isomer thereof, a pharmaceutical composi...
|
|
WO/2022/251576A1 |
Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosur...
|
|
WO/2022/249972A1 |
The present invention addresses the problem of providing: a photoelectric conversion element which has excellent photoelectric conversion efficiency, while achieving excellent suppression of electric field strength dependence of the phot...
|
|
WO/2022/243111A1 |
The present invention relates to the compounds of formula (I) wherein the variables are defined as given in the description and claims. The invention further relates to their use and composition.
|
|
WO/2022/243109A1 |
The present invention relates to the compounds of formula (I) wherein the variables are defined as given in the description and claims. The invention further relates to their use and composition.
|
